Many (not all) physician-/scientist-CEOs have a tendency to revert to their area of comfort by using highly scientific terminology and concepts in ways that derail from the purpose of the presentation: articulating the business case in a finite amount of meeting time.
There is no arguing that the last year has been a rocky one for biotech companies, but trends suggest that the sector is ready for an upswing. The revenue model works, innovation continues to bear fruit, and the need is ever-present. The harsh winter will result in a hearty harvest.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
An initial $300 million injection will set the development in motion and by 2021, the entire 2.25 million square-foot site is expected to be developed.
Several biotechnology companies secured impressive venture funding this quarter, despite the fact that biotech investment is flat, a new PwC report shows.
It's important to manage one's reputation on social media. Forbes published an amusing guide on biotech investment etiquette.
The timelines for biotech investment is getting shaken up, as new funding models enter the fray. These infographs lay out the change quite nicely.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.